Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BioNTech SE (BNTX) Stock Price & Analysis
4,157 Followers
BNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$85.21 - $125.83
Previous Close$92.72
Volume135.00
Average Volume (3M)596.12K
Market Cap
$22.08B
Enterprise Value$5.71B
Total Cash (Recent Filing)€16.55B
Total Debt (Recent Filing)€219.10M
Price to Earnings (P/E)180.3
Beta0.36
Next Earnings
Aug 05, 2024EPS Estimate
-$2.26Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding237,725,735
10 Day Avg. Volume521,271
30 Day Avg. Volume596,124
Standard Deviation0.23
R-Squared0.00336
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)5.77
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$111.55Price Target Upside20.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
BioNTech SE News
PremiumCompany Announcements
BioNTech SE Faces Q1 Loss, Advances Oncology Trials
PremiumCompany Announcements
BioNTech SE Reports Q1 Financial Shifts
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFirst patient dosed in BNT323 for HR+/HER2-low breast cancer represents progress in the company's clinical trials.
Financial StabilityBioNTech's valuation is believed to be higher than what the market currently attributes, indicating potential for stock price growth.
Product PipelineUpcoming presentations at the American Society for Clinical Oncology are expected to increase visibility for BioNTech's oncology franchise.
Bears Say
Financial UnderperformanceFor 1Q24, BioNTech recorded a net loss per diluted share of €1.31 per share—meaningfully worse than the previous forecast for net earnings of €1.18 per share.
Legal ChallengesGlaxoSmithKline plc filed a federal lawsuit alleging that Pfizer and BioNTech's COVID-19 vaccine, COMIRNATY, infringed U.S. patents.
Pipeline ConcernsThe majority of the company's oncology pipeline is in earlier-stages development and will take time to mature.
---
Ownership Overview
0.68% Insiders
4.49% Mutual Funds
8.70% Other Institutional Investors
86.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $85.21 and its highest was $125.83 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Aug 05, 2024 which is in 83 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on May 06, 2024. The company reported -$1.407 earnings per share for the quarter, missing the consensus estimate of -$1.335 by -$0.072.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.53 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -$2.26.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,725,740 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$1.407 in its last earnings report, missing expectations of -$1.335. Following the earnings report the stock price went up 0.679%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 503M.
---
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.55 (20.08% Upside)
$111.55 (20.08% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 81%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 101.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.89%
12-Months-Change
Fundamentals
Return on Equity
0.54%
Trailing 12-Months
Asset Growth
0.21%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q1 2024
0:00 / 0:00
---
BNTX Stock 12 Month Forecast
Average Price Target
$111.55
▲(20.08% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
+20.92%
reiterated a buy rating 9 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +20.92% per trade.
---